Susarla Srinivas M, August Meredith, Dewsnup Nathan, Faquin William C, Kaban Leonard B, Dodson Thomas B
Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
J Oral Maxillofac Surg. 2009 May;67(5):951-6. doi: 10.1016/j.joms.2008.12.045.
To evaluate the staining density of CD34, a glycoprotein expressed in hematopoetic precursor and capillary endothelial cells, as a molecular marker for predicting clinical behavior of giant cell tumors.
This was a retrospective study of patients with giant cell lesions of the jaws treated over a 15-year period. The primary predictor variable was mean CD34 staining density. The outcome measure was giant cell tumor clinical behavior (aggressive vs nonaggressive). Bivariate analyses were computed to evaluate the association between the predictors and outcome. A receiver-operator characteristic (ROC) curve was used to establish the threshold for a positive diagnostic test. A logistic regression model was used to evaluate the association between the clinical behavior and a positive test. A value of P <or= .05 was statistically significant.
The study sample consisted of 32 subjects with a mean age of 24.4 +/- 19.8 years (range 2-83), including 23 females (71.8%), treated for giant cell lesions during the study period. The sample included 26 aggressive lesions and 6 nonaggressive lesions, with mean CD34 staining densities of 5.1 +/- 3.3% and 2.2 +/- 0.7%, respectively (P = .02). Using a CD34 staining level of equal to or more than 2.5% as indicative of a positive test, the sensitivity, specificity, positive and negative predictive values were 0.77, 0.83, 0.95 and 0.45, respectively. CD34 levels of more than 2.5% were significantly associated with aggressive lesions whereas CD 34 levels of less than 2.5% were associated with nonaggressive lesions (odds ratio: 16.7, P = .04).
CD34 staining density levels of more than 2.5% were associated with aggressive giant cell lesions.
评估CD34的染色密度，CD34是一种在造血前体细胞和毛细血管内皮细胞中表达的糖蛋白，作为预测骨巨细胞瘤临床行为的分子标志物。
这是一项对15年间接受治疗的颌骨巨细胞病变患者的回顾性研究。主要预测变量是平均CD34染色密度。结果指标是骨巨细胞瘤的临床行为（侵袭性与非侵袭性）。进行双变量分析以评估预测因素与结果之间的关联。使用受试者操作特征（ROC）曲线来确定阳性诊断测试的阈值。使用逻辑回归模型评估临床行为与阳性测试之间的关联。P≤0.05的值具有统计学意义。
研究样本包括32名受试者，平均年龄为24.4±19.8岁（范围2 - 83岁），其中23名女性（71.8%）在研究期间接受了骨巨细胞病变治疗。样本包括26例侵袭性病变和6例非侵袭性病变，平均CD34染色密度分别为5.1±3.3%和2.2±0.7%（P = 0.02）。使用等于或高于2.5%的CD34染色水平作为阳性测试的指标，敏感性、特异性、阳性和阴性预测值分别为0.77、0.83、0.95和0.45。CD34水平高于2.5%与侵袭性病变显著相关，而CD34水平低于2.5%与非侵袭性病变相关（优势比：16.7，P = 0.04）。
CD34染色密度水平高于2.5%与侵袭性骨巨细胞病变相关。
